Related Experiment Video
Updated: Aug 15, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
[Interferon-based cytokine therapy for advanced renal cell carcinoma]
Tatsuya Takayama1, Fumitake Kai, Takayuki Sugiyama
1The Department of Urology, Hamamatsu University School of Medicine.
Hinyokika Kiyo. Acta Urologica Japonica
|September 17, 2005
Summary
Symptomatic status and multiple organ metastasis at diagnosis predict shorter survival in metastatic renal cell carcinoma patients. Treatment style did not impact survival, highlighting the need for new therapeutic strategies.
Area of Science:
- Oncology
- Medical Research
Context:
- Retrospective analysis of 126 patients with metastatic renal cell carcinoma (mRCC) diagnosed between 1978 and 2004.
- Data collected from Hamamatsu University and affiliated hospitals.
Purpose:
- To identify pretreatment prognostic factors associated with shorter survival in mRCC patients.
- To evaluate the influence of treatment style on survival outcomes.
Summary:
- Multivariate analysis identified symptomatic status at diagnosis and multiple organ metastasis as key predictors of reduced survival in mRCC.
- Patients with these prognostic factors had significantly lower 1-year (22.3%) and 3-year (0.3%) survival rates.
- Treatment modality did not demonstrate a significant impact on survival for this patient cohort.
Impact:
- Accurate prognostic assessment is crucial for managing patient expectations and guiding clinical decisions.
- Emphasizes the urgent need for developing novel therapeutic agents and treatment strategies for mRCC.
- Findings underscore the limitations of current treatments for advanced mRCC with poor prognostic indicators.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...